New Cross Linked Hyaluronan Gel After Deep Infiltrating Endometriosis Surgery
Palavras-chave
Resumo
Descrição
A prospective 1:1 randomised placebo-controlled study was conducted in our department during the study period January 2017-January 2019. All patients were included after obtaining written, signed informed consent before participating. All of the procedures were performed by the same surgery team who are experienced in minimally invasive (Deep infiltrating endometriosis) DIE surgery. The study protocol was approved by the local Ethics Committee of hospital (Approval number: 2017/04/35) 60 patients who were underwent for laparoscopic surgery for the treatment of deep infiltrating endometriosis without bowel involvement were recruited.
The inclusion criteria for this study were as follows, aged 18 to 45 years, and undergoing laparoscopic surgery for suspicious of DIE and persistent pain irrespective to any medical treatment. Patients were booked for follow-up visits at the 3rd and 6th month postoperative months and wanted to fill the questionnaires.
The exclusion criteria for the study were as; acute or severe infection, autoimmune disease, known/suspected intolerance or hypersensitivity to Hyaluronan or its derivatives, concurrent use of a systemic anti-inflammatory or hormonal drug at least 3 months prior to the surgery, clinical evidence of cancer; use of anticoagulant, fibrin glue, other thromboembolic agents, or any other anti-adhesion agent during the procedure ,patients with surgically diagnosed bowel involvement or need bowel resection, and who want to receive any postoperative hormonal treatment.
Participants were allowed to voluntarily withdraw from the trial for any reason at any time, and could be terminated by investigators owing to safety concerns, violations of inclusion/exclusion criteria, or pregnancy.
Surgical procedure The patients were laid low lithotomy position under general anesthesia. Patients were assigned at random to either the NCH gel or control group in a 1:1 ratio through a computer based program. A standardised technic with 4 abdominal incision laparoscopic approach with 10 mm umbilical trocar for the optic camera and three 5 mm axillary ports for the surgical instruments were used. All of the surgeries initiated from exploring the pelvic cavity, identification of the ureters and dissection transection of the pelvic adhesion by 5 mm bipolar cautery used at 25 kw for coagulation mode and scissors. The incision was begun on the left pelvic sidewall just cephalad to the last deposit. The incision was then extended towards the uterus, lateral and parallel to the left uterosacral ligament. The uterosacral ligament was pushed medially and down and the healthy tissues including the ureter were pushed upwards and laterally away from the dissection. It then transected the right utero-sacral ligament and was continued along the right pelvic sidewall just lateral and above the right uterosacral ligament until it extends beyond all obvious deposits. All of the endometriotic foci was grasped and pulled then undercut and freed so that the whole lesion and a surrounding margin of healthy tissue was removed. After an extensive bleeding control the Patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures. The patients in the control group had 40 cc sterile saline solution compatible with the body temperature. Operators could not be blinded to treatment allocation, but the questionnaire assessors and the patients were blinded to treatment allocation.
Pre and Postoperative assessment of pain and quality of life A dedicated research assisted in this study was asked the validated (visual analogue scale) VAS (dysmenorrhea, dyschezia, dyspareunia, dysuria, and pelvic pain), (endometriosis health profile-5) EHP-5 and (short form 12) SF-12 questionnaires before the day of the surgery. (12-14) A validated form of VAS score was used and scored from 0: No pain to 10: the worst pain all in their lives in a likert fashion. The VAS and (quality of life ) QoL questions were asked then in the 3rd and 6th month of during their follow up visits. A validated form of SF-12 that includes physical functioning, role limitation due to physical health problems, bodily pain, general health, vitality (energy/fatigue) social functioning, role limitations due to emotional problems and mental health (psychological distress or wellbeing) were asked. The questions are scored and analysed using a statistical algorithm to give two scores: the physical component summary and the mental component summary.
A validated form of EHP-5 questionnaire was used to determine endometriosis related QoL of the patients. EHP-5 consists of two parts: the first has a central questionnaire that evaluate five dimensions - pain, control and powerlessness, emotional well-being, social support, and self-image; and the second part measuring the areas of sexual intercourse, work, relationship with children, feelings about medical professional, treatment and infertility.
Statistical analysis Data analysis was performed by using SPSS (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.). A one-sample Kolmogorov-Smirnov test was performed to analyse the distribution of clinical variables. The frequency and percentage of the categorical variables and the mean, standard deviation, median and range values of the continuous and ordinal variables were presented. The study groups were compared using Student t test for parametric variables and Mann Whitney U test for the non-parametric variables. A post-hoc sample size calculation was performed via a two-sided Z test (α=0.05, β=0.20) for each study groups in order to obtain VAS scores as the primary outcome A p-value of < 0.05 was considered statistically significant for all calculations
datas
Última verificação: | 06/30/2019 |
Enviado pela primeira vez: | 07/12/2019 |
Inscrição estimada enviada: | 07/15/2019 |
Postado pela primeira vez: | 07/16/2019 |
Última atualização enviada: | 07/15/2019 |
Última atualização postada: | 07/16/2019 |
Data real de início do estudo: | 12/31/2016 |
Data Estimada de Conclusão Primária: | 12/31/2018 |
Data Estimada de Conclusão do Estudo: | 05/31/2019 |
Condição ou doença
Intervenção / tratamento
Drug: HyaRegen NCH gel group
Drug: Control
Fase
Grupos de Armas
Braço | Intervenção / tratamento |
---|---|
Placebo Comparator: Control The patients in the control group had 40 cc sterile saline solution compatible with the body temperature. | Drug: Control After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature. |
Experimental: HyaRegen NCH gel group In the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity through a large-bore cannula following standard laparoscopic procedures. | Drug: HyaRegen NCH gel group After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity. |
Critério de eleição
Idades qualificadas para estudar | 18 Years Para 18 Years |
Sexos elegíveis para estudo | Female |
Aceita Voluntários Saudáveis | sim |
Critério | Inclusion Criteria: - aged 18 to 45 years - undergoing laparoscopic surgery for suspicious of DIE - persistent pain irrespective to any medical treatment Exclusion Criteria: - acute or severe infection - autoimmune disease - known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives - concurrent use of a systemic anti-inflammatory or hormonal drug at least 3 months prior to the surgery - clinical evidence of cancer - use of anticoagulant, fibrin glue, other thromboembolic agents - use of any other anti-adhesion agent during the procedure - patients with surgically diagnosed bowel involvement or need bowel resection - patients who want to receive any postoperative hormonal treatment |
Resultado
Medidas de Resultado Primário
1. The preoperative and postoperative 6th month change of Visual Analogue Scale symptom score [The preoperative and postoperative 6th month change in Visual Analogue Scale symptom score]
Medidas de Resultado Secundário
1. Short Form-12 Quality of Life [The preoperative and postoperative 6th month change of Short Form-12 Quality of Life questions were recorded considering follow up visits.]